Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.24 -3.1%	$0.27	$0.20 ▼ $1.48	$64.22M	2.24	1.71 million shs	564,916 shs
CING Cingulate	$4.20 -4.5%	$4.05	$1.80 ▼ $20.83	$17.83M	-0.85	1.10 million shs	66,670 shs
EPIX ESSA Pharma	$1.67 -1.8%	$1.70	$1.40 ▼ $7.88	$74.13M	1.58	339,266 shs	39,103 shs
GNTA Genenta Science	$3.88 +1.4%	$4.12	$2.79 ▼ $7.28	$70.87M	0.73	14,949 shs	853 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-1.46%	-14.38%	-10.92%	-46.19%	-76.70%
CING Cingulate	-4.55%	-3.67%	-1.18%	+16.99%	+506.76%
EPIX ESSA Pharma	-1.76%	-2.34%	-2.91%	+3.09%	-67.88%
GNTA Genenta Science	-0.13%	-22.65%	-9.57%	+1.04%	+23.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.1309 of 5 stars	4.2	5.0	2.2	0.8	0.0
CING Cingulate	2.0967 of 5 stars	3.5	2.0	2.5	0.8	0.6
EPIX ESSA Pharma	1.997 of 5 stars	2.0	3.0	2.7	2.5	1.3
GNTA Genenta Science	2.7639 of 5 stars	3.5	5.0	2.2	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.43	Hold	$1.52	526.63% Upside
CING Cingulate	3.00	Buy	$26.00	519.05% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	19.76% Upside
GNTA Genenta Science	3.00	Buy	$25.00	545.16% Upside

Current Analyst Ratings Breakdown

Latest CING, EPIX, ADAP, and GNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00
5/19/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
4/21/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $60.00
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.36	N/A	N/A	$0.17 per share	1.43
CING Cingulate	N/A	N/A	N/A	N/A	($70.63) per share	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.68 per share	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	$1.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	8/11/2025 (Estimated)
CING Cingulate	-$23.53M	-$8.48	N/A	N/A	N/A	N/A	-570.20%	-236.15%	8/12/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-24.61%	-23.87%	8/4/2025 (Estimated)
GNTA Genenta Science	-$12.60M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest CING, EPIX, ADAP, and GNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/8/2025	Q1 2025	CING Cingulate	-$1.00	-$1.04	-$0.04	-$1.04	N/A	N/A
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
CING Cingulate	N/A	7.35	7.35
EPIX ESSA Pharma	N/A	33.12	33.12
GNTA Genenta Science	N/A	9.31	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CING Cingulate	41.31%
EPIX ESSA Pharma	75.12%
GNTA Genenta Science	15.13%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
CING Cingulate	5.27%
EPIX ESSA Pharma	15.50%
GNTA Genenta Science	28.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	224.05 million	Optionable
CING Cingulate	20	4.25 million	2.66 million	Not Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable

CING, EPIX, ADAP, and GNTA Headlines

Recent News About These Companies

Reviewing Vaxcyte (NASDAQ:PCVX) and Genenta Science (NASDAQ:GNTA)

June 13 at 1:33 AM | americanbankingnews.com

Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Update

June 4, 2025 | marketbeat.com

GNTA Genenta Science S.p.A.

May 30, 2025 | seekingalpha.com

Genenta Science (NASDAQ:GNTA) Stock Price Up 7% - Here's Why

May 16, 2025 | marketbeat.com

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

May 8, 2025 | newsfilecorp.com

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

May 7, 2025 | globenewswire.com

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

April 15, 2025 | globenewswire.com

Genenta Science announces EUR 20M financing to expand pipeline

March 21, 2025 | markets.businessinsider.com

Genenta Science Secures €20 Million Convertible Bond Financing for Oncology Research

March 19, 2025 | tipranks.com

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

March 19, 2025 | globenewswire.com

Is Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?

February 13, 2025 | msn.com

Genenta Science SpA ADR

February 1, 2025 | investing.com

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

January 28, 2025 | prnewswire.com

Genenta Science announces amendment to pact with AGC Biologics

January 10, 2025 | finance.yahoo.com

Genenta, AGC Biologics Strengthen Cell Therapy Manufacturing Pact

January 9, 2025 | contractpharma.com

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

January 9, 2025 | globenewswire.com

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

January 8, 2025 | prnewswire.com

Genenta Science Enhances Manufacturing Agreement with AGC Biologics

January 1, 2025 | markets.businessinsider.com

Genenta Science Updates ATM Sales Agreement with New Agent

December 20, 2024 | tipranks.com

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

October 23, 2024 | globenewswire.com

Genenta Science (NASDAQ:GNTA) Stock Quotes, Forecast and News Summary

October 11, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
By Jeffrey Neal Johnson | June 4, 2025
View Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge
Hims & Hers Stock: Buy the Dip or Wait It Out?
By Gabriel Osorio-Mazilli | June 5, 2025
View Hims & Hers Stock: Buy the Dip or Wait It Out?
Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
By Jeffrey Neal Johnson | June 8, 2025
View Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later?
Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes
By Gabriel Osorio-Mazilli | June 9, 2025
View Is Lululemon’s 18% Selloff Overdone? Analysts Say Yes
AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway
By Leo Miller | June 10, 2025
View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway

CING, EPIX, ADAP, and GNTA Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.24 -0.01 (-3.08%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$0.25 +0.01 (+3.18%)

As of 06/13/2025 07:40 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Cingulate NASDAQ:CING

$4.20 -0.20 (-4.55%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$4.38 +0.18 (+4.19%)

As of 06/13/2025 07:38 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

ESSA Pharma NASDAQ:EPIX

$1.67 -0.03 (-1.76%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.67 0.00 (0.00%)

As of 06/13/2025 04:08 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Genenta Science NASDAQ:GNTA

$3.81 -0.01 (-0.26%)

As of 06/13/2025 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time